IP Library Granted Patent US 10,376,516
Granted Patent B2
US 10,376,516 · App. 15/960,596 · Granted Aug 13, 2019

Methods and devices for renal nerve blocking

Inventors: Mark Gelfand (New York, NY); Howard R. Levin (Teaneck, NJ)
Assignee: Medtronic Ardian Luxembourg S.a.r.l.
A61K31/529A61K9/0004A61K9/0012A61K9/7007A61K31/135A61K31/52A61K45/06A61L29/146A61M5/145A61M5/14276A61M5/1723A61N1/326A61N1/36114A61M2005/14513A61M2205/05A61M2205/50A61M2210/1082A61N1/0551A61N1/36007A61N1/3627A61N1/36117
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,376,516
App. No.
15/960,596
Granted
Aug 13, 2019
Kind
B2
Abstract

Methods for treating a hypertensive human patient are disclosed herein. A method in accordance with one embodiment comprises delivering a neuromodulatory agent to a renal nerve of the patient via an intravascularly positioned drug delivery catheter. The method includes at least partially blocking neural activity along the renal nerve with the neuromodulatory agent, which results in a therapeutically beneficial reduction in blood pressure of the patient.

Claims (23)

1. A method, comprising:

delivering a neuromodulatory agent to a renal nerve of a hypertensive human patient via a drug delivery catheter; and

at least partially blocking neural activity along the renal nerve to and from a kidney of the patient with the neuromodulatory agent,

wherein at least partially blocking neural activity along the renal nerve results in a therapeutically beneficial reduction in blood pressure of the patient.

2. The method of claim 1 , further comprising removing the drug delivery catheter from the patient after delivering the neuromodulatory agent to conclude the procedure.

3. The method of claim 1 , further comprising positioning the drug delivery catheter under guidance imaging before delivering the neuromodulatory agent.

4. The method of claim 3 wherein positioning the drug delivery catheter under guidance imaging comprises positioning the drug delivery catheter under fluoroscopic guidance.

5. The method of claim 1 , further comprising determining whether neural activity along the renal nerve has been substantially blocked.

6. The method of claim 5 wherein determining whether neural activity has been substantially blocked comprises electrically stimulating the renal nerve and detecting a response in the patient.

7. The method of claim 1 , further comprising monitoring a parameter of the drug delivery catheter and/or tissue within the patient before and during delivery of the neuromodulatory agent.

8. The method of claim 7 , further comprising altering delivery of the neuromodulatory agent in response to the monitored parameter.

9. The method of claim 1 wherein at least partially blocking neural activity along the renal nerve comprises at least substantially blocking sympathetic neural activity along the renal nerve of the patient.

10. The method of claim 1 wherein delivering a neuromodulatory agent to a renal nerve of a hypertensive human patient comprises delivering a neurotoxin to the renal nerve of the patient.

11. The method of claim 1 wherein delivering a neuromodulatory agent to a renal nerve of a hypertensive human patient comprises delivering alcohol to the renal nerve of the patient.

12. The method of claim 1 wherein delivering a neuromodulatory agent to a renal nerve of a hypertensive human patient comprises delivering phenol, ketamine, and/or an antidepressant to the renal nerve of the patient.

13. The method of claim 1 wherein at least partially blocking neural activity along the renal nerve with the neuromodulatory agent comprises denervating a kidney of the patient.

14. The method of claim 1 wherein at least partially blocking neural activity along the renal nerve with the neuromodulatory agent comprises ablating the renal nerve via the neuromodulatory agent.

15. The method of claim 1 wherein at least partially blocking neural activity along the renal nerve with the neuromodulatory agent further results in a reduction of systemic sympathetic tone in the patient.

16. The method of claim 1 , further comprising positioning at least a portion of the drug delivery catheter within a periarterial space of the patient before delivering the neuromodulatory agent.

17. The method of claim 16 wherein positioning at least a portion of the drug delivery catheter within the periarterial space comprises positioning a distal tip of the drug delivery catheter within renal fascia of the patient.

18. The method of claim 16 wherein positioning at least a portion of the drug delivery catheter within the periarterial space comprises positioning a distal tip of the drug delivery catheter within a target site in continuity with a periarterial fat tissue layer surrounding a renal pedicle of the patient.

19. The method of claim 1 wherein delivering a neuromodulatory agent to a renal nerve of a hypertensive human patient comprises positioning a needle within a periarterial space of the patient and injecting the neuromodulatory agent via the needle into the periarterial space of the patient.

20. The method of claim 19 wherein positioning a needle within a periarterial space of the patient comprises positioning the needle under CT guidance.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2019
From: GELFAND, MARK; LEVIN, HOWARD R.
To: G&L CONSULTING, LLC
Reel/Frame 049464/0449 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2019
From: G&L CONSULTING, LLC
To: FOUNDRY NEWCO 8, INC.
Reel/Frame 049464/0524 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2019
From: MEDTRONIC ARDIAN LLC
To: MEDTRONIC ARDIAN LUXEMBOURG S.A.R.L.
Reel/Frame 049464/0847 →
CHANGE OF NAME Recorded Jun 13, 2019
From: FOUNDRY NEWCO VIII, INC.
To: ARDIAN, INC.
Reel/Frame 049471/0762 →
CHANGE OF NAME Recorded Jun 13, 2019
From: ARDIAN, INC.
To: MEDTRONIC ARDIAN LLC
Reel/Frame 049471/0765 →
Continuity (9)
Continuation 14878371 · Oct 8, 2015
Continuation 14221536 · Mar 21, 2014
Continuation 11133925 · May 20, 2005
Continuation 10900199 · Jul 28, 2004
Continuation In Part 10408665 · Apr 8, 2003
Provisional Application 60370190 · Apr 8, 2002
Provisional Application 60415575 · Oct 3, 2002
Provisional Application 60442970 · Jan 29, 2003
Related Publication 20180303839A1 · Oct 25, 2018
Cited By (3)
US 12,408,974 US 12,478,806 US 12,539,167